Challenges in modelling the pharmacokinetics of isoniazid in South African tuberculosis patients

Similar documents
; Model description: Study ACTG 5267: BDQ + M2 + M3. ; Elin Svensson, Pharmacometrics Research Group, Uppsala University. $PROB Study ACTG5267

TMDD Model Translated from NONMEM (NM- TRAN) to Phoenix NLME (PML)

Supplementary material. Table S1: Gentamicin analytical techniques. Figure S1: An example of the neogent output.

Description of UseCase models in MDL

3 Results. Part I. 3.1 Base/primary model

The general concept of pharmacokinetics

Population Approach. Pharmacokinetics. Analysis Approaches. Describing The Signal and the Noise

Clinical Pharmacokinetics. Supplemental Digital Content. V. Pilla Reddy, et al.

Integration of SAS and NONMEM for Automation of Population Pharmacokinetic/Pharmacodynamic Modeling on UNIX systems

Multicompartment Pharmacokinetic Models. Objectives. Multicompartment Models. 26 July Chapter 30 1

A Novel Screening Method Using Score Test for Efficient Covariate Selection in Population Pharmacokinetic Analysis

! "! # $ % '()*% +,-'"& %.% /)01( ).%.) %')1/ ) %'%

Nonlinear Mixed Effects Models

Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development Part 2: Introduction to Pharmacokinetic Modeling Methods

DESIGN EVALUATION AND OPTIMISATION IN CROSSOVER PHARMACOKINETIC STUDIES ANALYSED BY NONLINEAR MIXED EFFECTS MODELS

Population Pharmacokinetics in Support of Analgesics and Anaesthetics Studies in

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients

Pharmacometrics : Nonlinear mixed effect models in Statistics. Department of Statistics Ewha Womans University Eun-Kyung Lee

PK-QT analysis of bedaquiline : Bedaquiline appears to antagonize its main metabolite s QTcF interval prolonging effect

F. Combes (1,2,3) S. Retout (2), N. Frey (2) and F. Mentré (1) PODE 2012

THE IMPORTANCE OF THE SIMULATION EXPECTATION AS A GOODNESS OF FIT DIAGNOSTIC FOR CATEGORICAL POPULATION PHARMACODYNAMIC MODELS

Pharmacokinetics Introduction to

CTP-656 Tablet Confirmed Superiority Of Pharmacokinetic Profile Relative To Kalydeco in Phase I Clinical Studies

A comparison of estimation methods in nonlinear mixed effects models using a blind analysis

Principles of Covariate Modelling

Nonlinear pharmacokinetics

Machine search vs. humans in modeling or I m sorry Dave, I m afraid I. can t do that. Mark Sale M.D. Next Level Solutions.

An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments

Research Paper. Stochastic Differential Equations in NONMEM \ : Implementation, Application, and Comparison with Ordinary Differential Equations

Correction of the likelihood function as an alternative for imputing missing covariates. Wojciech Krzyzanski and An Vermeulen PAGE 2017 Budapest

Handling parameter constraints in complex/mechanistic population pharmacokinetic models

PHA 4123 First Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Heterogeneous shedding of influenza by human subjects and. its implications for epidemiology and control

Fitting PK Models with SAS NLMIXED Procedure Halimu Haridona, PPD Inc., Beijing

Homework 1 (PHA 5127)

How Critical is the Duration of the Sampling Scheme for the Determination of Half-Life, Characterization of Exposure and Assessment of Bioequivalence?

Package wnl. April 2, 2018

Estimation and Model Selection in Mixed Effects Models Part I. Adeline Samson 1

IVIVC Industry Perspective with Illustrative Examples

Noncompartmental vs. Compartmental Approaches to Pharmacokinetic Data Analysis Paolo Vicini, Ph.D. Pfizer Global Research and Development David M.

Nonlinear mixed-effects models using Stata

Confidence and Prediction Intervals for Pharmacometric Models

An Approach for Identifiability of Population Pharmacokinetic-Pharmacodynamic Models

Noncompartmental vs. Compartmental Approaches to Pharmacokinetic Data Analysis Paolo Vicini, Ph.D. Pfizer Global Research and Development David M.

NONLINEAR MODELS IN MULTIVARIATE POPULATION BIOEQUIVALENCE TESTING

Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations

Beka 2 Cpt: Two Compartment Model - Loading Dose And Maintenance Infusion

Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects Panhard Xavière

Generalizing the MCPMod methodology beyond normal, independent data

Phase I design for locating schedule-specific maximum tolerated doses

Inflammation and organ failure severely affect midazolam clearance in critically ill children

Modelling a complex input process in a population pharmacokinetic analysis: example of mavoglurant oral absorption in healthy subjects

Research Article. Multiple Imputation of Missing Covariates in NONMEM and Evaluation of the Method s Sensitivity to η-shrinkage

MA/ST 810 Mathematical-Statistical Modeling and Analysis of Complex Systems

Predicting the Onset of Nonlinear Pharmacokinetics

Generalizing the MCPMod methodology beyond normal, independent data

Bayesian pharmacometric modeling with BUGS, NONMEM and Stan

METHODS FOR POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS

Compare Predicted Counts between Groups of Zero Truncated Poisson Regression Model based on Recycled Predictions Method

Robust design in model-based analysis of longitudinal clinical data

Covariate Model Building in Nonlinear Mixed Effects Models

Evaluation of the Fisher information matrix in nonlinear mixed eect models without linearization

APPLICATION OF LAPLACE TRANSFORMS TO A PHARMACOKINETIC OPEN TWO-COMPARTMENT BODY MODEL

Plot of Laser Operating Current as a Function of Time Laser Test Data

Covariate selection in pharmacometric analyses: a review of methods

Torsten: Stan functions for pharmacometrics applications

Current approaches to covariate modeling

Modeling biological systems - The Pharmaco-Kinetic-Dynamic paradigm

The Calculus Behind Generic Drug Equivalence

Nonlinear random effects mixture models: Maximum likelihood estimation via the EM algorithm

Package nmw. October 20, 2017

Individualization of fixed-dose combination regimens

Introduction to PK/PD modelling - with focus on PK and stochastic differential equations

Individual bioequivalence testing under 2 3 designs

Efficient algorithms for calculating optimal designs in pharmacokinetics and dose finding studies

Technical Report - 7/87 AN APPLICATION OF COX REGRESSION MODEL TO THE ANALYSIS OF GROUPED PULMONARY TUBERCULOSIS SURVIVAL DATA

PHAR 7633 Chapter 12 Physical-Chemical Factors Affecting Oral Absorption

Estimating terminal half life by non-compartmental methods with some data below the limit of quantification

On drug transport after intravenous administration

Analysing repeated measurements whilst accounting for derivative tracking, varying within-subject variance and autocorrelation: the xtiou command

arxiv: v1 [stat.me] 10 Apr 2013

Bayesian Drug Disease Model with Stan Using published longitudinal data summaries in population models

Bayesian Inference on Joint Mixture Models for Survival-Longitudinal Data with Multiple Features. Yangxin Huang

Chapter 5. Pharmaceutical Measurements and Calculations. Paradigm Publishing, Inc. 1

Pharmaceutical Calculations Chapters

A simple PK/PD model identification procedure for controller design in anesthesia

gáfãªï UÁA ü DgÉÆÃUÀå «eáõ ÀUÀ¼À «±Àé«zÁå AiÀÄ, PÀ ÁðlPÀ 4 Éà "n" ÁèPï, daiàä ÀUÀgÀ, ÉAUÀ¼ÀÆgÀÄ

STUDY OF THE APPLICABILTY OF CONTENT UNIFORMITY AND DISSOLUTION VARIATION TEST ON ROPINIROLE HYDROCHLORIDE TABLETS

Nonparametric Bayes approach for a semimechanistic pharmacodynamic model

Introduction to Statistical Population Modeling and Analysis for Pharmacokinetic Data

University of North Carolina at Chapel Hill

Opportunities for Regulatory Relief via In Vitro Dissolution. James E. Polli June 10, 2015

Course Plan for Pharmacy (Bachelor Program) No.: (2016/2017) Approved by Deans Council by decision (09/26/2016) dated (03/08/2016) )160) Credit Hours

Validation of the GastroPlus TM Software Tool and Applications

SEM 2: Structural Equation Modeling

MODELING THE ABSORPTION, CIRCULATION, AND METABOLISM OF TIRAPAZAMINE

On Assessing Bioequivalence and Interchangeability between Generics Based on Indirect Comparisons

TK Solver Case Study: Pharmacokinetics

PHARMACOKINETIC DERIVATION OF RATES AND ORDERS OF REACTIONS IN MULTI- COMPARTMENT MODEL USING MATLAB

Research Article. A Minimal Continuous-Time Markov Pharmacometric Model

Transcription:

PAGE 2005 Pamplona, Spain Challenges in modelling the pharmacokinetics of isoniazid in South African tuberculosis patients Justin J Wilkins 1, Grant Langdon 1, Helen McIlleron 1, Goonaseelan Pillai 2, Peter J Smith 1 and Ulrika S H Simonsson 3 (1) Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa (2) Modelling & Simulation, Clinical Development & Medical Affairs, Novartis Pharmaceuticals AG, Basel, Switzerland (3) Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Sweden

Isoniazid (INH) N H 2 H N N O Key part of first-line tuberculosis chemotherapy Rapidly and completely absorbed from the intestine Subject to first-pass effect Substantial presystemic metabolism occurs in intestinal mucosal cells Subject to metabolic polymorphism trimodal

Patient Data 266 pulmonary tuberculosis (PTB) patients on first-line chemotherapy On treatment for 8-108 days prior to start of study 200-400 mg p.o. daily Samples for PK analysis were taken over between 1 and 6 weeks

Representative Individual Profiles 12 Dose: 300mg 10 INH Concentration (mg/l) 8 6 4 2 0 72 74 76 78 80 Day 4 Time (h)

Modelling Procedure 2-compartment model with first- order absorption & elimination IOV/IIV Enterohepatic circulation INH PK Model Complex absorption Acetylator phenotype Covariate relations Model assessment criteria OFV GOF plots Scientific plausibility Precision & accuracy

Complex absorption Modelled using dual absorption compartments fast and slow, characterized by absorption half- lives HL and HL HL a,fast and HL a,slow HL a,slow Slow Dose V 1 Fast HL a,fast V 2 F slow = 1 - F fast HLFAST = THETA(3) HLSLOW = THETA(4)+ )+HLA1

Other Aspects IOV/IIV IOV/IIV characterization was a key objective 27 dosing occasions, IOV on 2 parameters 56 ETA parameters needed ( ) ( CL = θ η / F CL / + κ / F CL F ) CL/ F exp i ij i Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993 Dec;21(6):735-50.

Other Aspects Acetylator phenotype Fast, intermediate and slow Data did not allow identification of intermediate group (indistinguishable from fast group) $MIX NSPOP = 2 P(1) = THETA(8) P(2) = 1 - THETA(8)

Other Aspects Enterohepatic circulation Several models tested to account for enterohepatic circulation (EHC) EHC models were unable to produce either a substantial OFV or a successful covariance step No literature evidence

Covariate relations GAM as implemented in Xpose used to identify potential covariate relations Screened using stepwise covariate modelling (SCM) method TV CL/ F = θ / 1+ θ WT WT ( ) ( ) ( ) θ θ TV V F = + SEX / V/ F SEX CL F WT med

The Model Dose Slow Absorption Fast Absorption F slow = 1 - F fast F fast IIV HL a,slow HL a,fast IIV IOV k 12 Sex IIV Central V 1 k 21 Peripheral V 2 Weight IIV IOV (CL/F) fast (CL/F) slow P CL

Goodness-of of-fit 15 15 DV (mg/l) 10 5 DV (mg/l) 10 5 0 0 0 2 4 6 8 10 PRED (mg/l) 0.5 3.0 5.5 8.0 10.5 13.0 15.5 IPRED (mg/l) 10 5 IWRES 8 6 4 2 0 0.5 3.0 5.5 8.0 10.5 13.0 15.5 IPRED (mg/l) WRES 3 1-1 -3-5 100 300 500 700 900 Time (h)

Goodness-of of-fit INH Concentration (mg/l) 8 6 4 2 0 DV PRED IPRED INH Concentration (mg/l) 6 4 2 0 DV PRED IPRED 72 74 76 78 80 Time (h) 72 74 76 78 80 Time (h) INH Concentration (mg/l) 8 6 4 2 0 72 74 76 78 80 Time (h) DV PRED IPRED INH Concentration (mg/l) 5 4 3 2 1 0 72.5 73.5 74.5 75.5 Time (h) DV PRED IPRED

Parameter Estimates Parameter Mean % RSE IIV (IOV) Oral clearance (CL( Oral clearance (CL( CL fast /F CL slow /F /F,, L.h - 1 ) /F,, L.h - 1 ) 10.4 4.42 2.90 3.48 0.156 (0.0327) Ratio of fast acetylators to slow acetylators (P( CL ) 0.225 14.9 Half-life life of absorption for fast compartment (HL(, h) HL a,fast,fast, h) 0.518 4.15 0.551 (0.351) Half-life life of absorption for slow compartment (HL(, h) HL a,slow,slow, h) 5.78 5.55 1.09 Dose fraction, fast cpt (F fast ) 0.526 3.73 Apparent volume of distribution, central compartment (V 1 /F,, L) 6.86 9.31 0.268 Apparent volume of distribution, peripheral compartment (V 2 /F,, L) 13.0 Fixed Intercompartmental rate constant (k( 12, h - 1 ) 2.43 12.2 Intercompartmental rate constant (k( 21, h - 1 ) 1.75 8.51 Residual Variability Constant coefficient of variability 0.191 3.03

The Final Model IOV/IIV Enterohepatic circulation INH PK Model Complex absorption Acetylator phenotype Covariate relations SCM Parsimonious Model for INH PK

Acknowledgments Aspects of this project were funded by the Medical Research Council of South Africa. Grateful thanks to Jean van Dyk, Afia Fredericks and the patients and staff of D P Marais SANTA Centre and Brewelskloof Hospital for the input, support and cooperation they have lent this work.

Complex Absorption 12 Dose: 300mg 10 INH Concentration (mg/l) 8 6 4 2 0 72 74 76 78 80 Day 4 Time (h)

Time = 48 0 + h θ GBL h k 41 Depot (V1) Enterohepatic circulation k a Gall Bladder (V4) Q k 24 Central (V2) Peripheral (V3) CL/F Dummy Dose GB4on (V5) ALAG5 = 4.0001 GB8on (V7) ALAG7 = 8.0001 Dummy Dose Dummy Dose GB4off (V6) ALAG6 = ALAG5 + θ GBL GB8off (V8) ALAG8 = ALAG7 + θ GBL Dummy Dose Adapted from the multiple-dose enterohepatic circulation model suggested by Luann Phillips (after Stuart Beal). NMusers, 11 June 2002. [ http://www.cognigencorp.com/nonmem/nm/98may312002.html ]

Bimodal absorption F2 = THETA(5) ; F for fast comp F3 = (1-F2) ; F for slow comp HLA1 = THETA(3)*EXP(BSV + BOV) ; abs half-life life of fast abs comp HLA2 = THETA(4)*EXP(ETA(4)) + HLA1 ; abs half-life life of slow abs comp K21 = 0.693/HLA1 K31 = 0.693/HLA2

Modelling Issues: IOV $OMEGA BLOCK(1).04 $OMEGA BLOCK(1) SAME $OMEGA BLOCK(1) SAME $PK BSV = ETA(1) BOV = ETA(5) IF (OCC.EQ.2) BOV = ETA(6) IF (OCC.EQ.3) BOV = ETA(7) IF (OCC.EQ.4) BOV = ETA(8) HLA1 = THETA(3)*EXP(BSV + BOV)

Modelling Issues: Acetylator Phenotype $MIX NSPOP = 2 P(1) = THETA(8) P(2) = 1 - THETA(8) Q1 = 0 Q2 = 0 IF (MIXNUM.EQ.1) Q1 = 1 IF (MIXNUM.EQ.2) Q2 = 1 CL1 = THETA(1) CL2 = THETA(9) TVCL = ((CL1*Q1) + (CL2*Q2)) * (1+ THETA(11)*(WT-50)) CL = TVCL*EXP(BSV2 + BOV2)

Full Final Model $PROB INH FINAL $DATA inh_dual_jun04.csv IGNORE=@ $INPUT ID IDNO=DROP OCCO=DROP DAY=DROP RATE=DROP TIME TT=DROP DV MDV AMT CMT EVID AGE SEX WT HT=DROP BMI=DROP RACE=DROP SMOK ALC PKG=DROP HIV HB=DROP HCT RBC=DROP MCV=DROP WBC=DROP AP=DROP ALT=DROP AST CRT=DROP TBIL=DROP UREA=DROP RIFP=DROP PZAP FDC DS=DROP LOC OCCD=DROP CLCR BSA=DROP OCC DRUG $SUBROUTINE ADVAN6 TRANS1 TOL=5 $MODEL COMP = (CENT) COMP = (ABS1); fast abs comp COMP = (ABS2); slow abs comp COMP = (PERI) $THETA (0, 4.6) ;1 CL1 $THETA (0, 21.2) ;2 V1 $THETA (0, 0.3) ;3 HLA1 $THETA (0, 6.1) ;4 HLA2 $THETA (0,.6, 1) ;5 F-fast $THETA (0 FIX) ;6 ADD error $THETA (0, 0.22) ;7 CCV error $THETA (0, 0.23, 1) ;8 P1 $THETA (0, 11) ;9 CL2 $THETA 0.01 ;10 SEX on V1 $THETA 0.01 ;11 WT on CL $THETA 13 FIX ;12 V2 $THETA (0, 2.5) ;13 K14 $THETA (0, 1.8) ;14 K41 $OMEGA.2.3.5 1.35 $OMEGA BLOCK(1).04 $OMEGA BLOCK(1) SAME $OMEGA BLOCK(1) SAME

Full Final Model < many $OMEGA BLOCK(1) records omitted > $OMEGA BLOCK(1) SAME $OMEGA BLOCK(1) SAME $SIGMA 1 FIX $ABBREVIATED DERIV2=NO $MIX NSPOP = 2 P(1) = THETA(8) P(2) = 1 - THETA(8) $PK BSV = ETA(1) BOV = ETA(5) IF (OCC.EQ.2) BOV = ETA(6) IF (OCC.EQ.3) BOV = ETA(7) IF (OCC.EQ.4) BOV = ETA(8) IF (OCC.EQ.5) BOV = ETA(9) IF (OCC.EQ.6) BOV = ETA(10) < many $ETA statements omitted > IF (OCC.EQ.26) BOV = ETA(30) IF (OCC.EQ.27) BOV = ETA(31) BSV2 = ETA(3) BOV2 = ETA(32) IF (OCC.EQ.2) BOV2 = ETA(33) IF (OCC.EQ.3) BOV2 = ETA(34) < many $ETA statements omitted > IF (OCC.EQ.26) BOV2 = ETA(57) IF (OCC.EQ.27) BOV2 = ETA(58) Q1 = 0 Q2 = 0 IF (MIXNUM.EQ.1) Q1 = 1 IF (MIXNUM.EQ.2) Q2 = 1 MXN=0 IF (MIXNUM.EQ.1) MXN=1 IF (MIXNUM.EQ.2) MXN=2

Full Final Model CL1 = THETA(1) ; CL1 CL2 = THETA(9) ; CL2 TVCL = ((CL1*Q1) + (CL2*Q2)) * (1+ THETA(11)*(WT-50)) CL = TVCL*EXP(BSV+BOV) TVV1 = THETA(2) + THETA(10)*SEX ; V1 V1 = TVV1*EXP(ETA(2)) ; V1 ; abs half-life of fast abs comp HLA1 = THETA(3)*EXP(BSV2+BOV2) ; abs half-life of slow abs comp HLA2 = THETA(4)*EXP(ETA(4))+HLA1 K21 = 0.693/HLA1 K31 = 0.693/HLA2 V2 = THETA(12) K14 = THETA(13) K41 = THETA(14) F2 = THETA(5) ; F for fast abs F3 = (1-F2) ; F for slow comp S1 = V1 K10 = CL/V1 $ERROR AA1 = A(1) AA2 = A(2) AA3 = A(3) AA4 = A(4) CP = A(1)/V1 IPRED = A(1)/S1+0.00001 IRES = DV-IPRED W = SQRT(THETA(6)**2 + THETA(7)**2*IPRED*IPRED) IWRES = IRES/W Y = IPRED+W*EPS(1) $DES DADT(1) = K21*A(2) + K31*A(3) - K10*A(1) K14*A(1) + K41*A(4) DADT(2) = -K21*A(2) DADT(3) = -K31*A(3) DADT(4) = K14*A(1) - K41*A(4)

Full Final Model $EST POSTHOC NOABORT PRINT=10 MAXEVAL=9999 MSFO=run526.msf SIGDIG=3 $COV PRINT=E MATRIX=S $TABLE ID TIME IPRED IWRES ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA33 OCC AA1 AA2 AA3 AA4 NOPRINT ONEHEADER FILE=sdtab526 $TABLE ID CL V1 HLA1 HLA2 F2 F3 K21 K31 K10 K14 K41 V2 MXN NOPRINT ONEHEADER FILE=patab526 $TABLE ID AGE WT HCT AST NOPRINT ONEHEADER FILE=cotab526 $TABLE ID SEX SMOK ALC HIV PZAP FDC LOC NOPRINT ONEHEADER FILE=catab526 $TABLE ID AUC CP NOPRINT ONEHEADER FILE=run526.fit